Incidence of seizure exacerbation and seizures reported as adverse events during adjunctive treatment with eslicarbazepine acetate: A pooled analysis of three Phase III controlled trials.
about
Incidence of seizure exacerbation and seizures reported as adverse events during adjunctive treatment with eslicarbazepine acetate: A pooled analysis of three Phase III controlled trials.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Incidence of seizure exacerbat ...... e Phase III controlled trials.
@en
Incidence of seizure exacerbat ...... e Phase III controlled trials.
@nl
type
label
Incidence of seizure exacerbat ...... e Phase III controlled trials.
@en
Incidence of seizure exacerbat ...... e Phase III controlled trials.
@nl
prefLabel
Incidence of seizure exacerbat ...... e Phase III controlled trials.
@en
Incidence of seizure exacerbat ...... e Phase III controlled trials.
@nl
P2093
P2860
P356
P1433
P1476
Incidence of seizure exacerbat ...... ee Phase III controlled trials
@en
P2093
David Blum
Francisco Rocha
Hailong Cheng
Selim Benbadis
Study 301, 302 and 304 Investigators (Appendix 1)
P2860
P304
P356
10.1002/EPI4.12083
P50
P577
2017-11-09T00:00:00Z